

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

Ca Ski

RRID:CVCL_1100

Type: Cell Line

Proper Citation

RRID:CVCL_1100

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1100

Proper Citation: RRID:CVCL_1100

Description: Cell line Ca Ski is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Human papillomavirus-related cervical squamous cell carcinoma

Defining Citation: [PMID:867042](#), [PMID:2990217](#), [PMID:3029430](#), [PMID:3371749](#), [PMID:7751322](#), [PMID:9887230](#), [PMID:10423141](#), [PMID:15531914](#), [PMID:17311676](#), [PMID:17611311](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21439369](#), [PMID:22412903](#), [PMID:24134916](#), [PMID:24201445](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:29156801](#), [PMID:30894373](#), [PMID:35839778](#)

Comments: Virology: Contains from 100 to 800 copies of the HPV16 genome; some complete and others truncated., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Space-flown cell line (cellonaut).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Ca Ski

Synonyms: Ca-Ski, CaSki, Caski, CASKI

Cross References: BTO:BTO_0003109, CLO:CLO_0002165, CLO:CLO_0002201, CLO:CLO_0050930, EFO:EFO_0006549, CLDB:cl603, CLDB:cl604, CLDB:cl605, CLDB:cl4940, AddexBio:C0008004/375, ArrayExpress:E-MTAB-783, ArrayExpress:E-

MTAB-2706, ArrayExpress:E-MTAB-3610, ATCC:CRL-1550, ATCC:CRL-7915, ATCC:CRM-CRL-1550, BCRC:60251, BioSample:SAMN01821540, BioSample:SAMN01821672, BioSample:SAMN01821725, BioSample:SAMN03473214, cancercellines:CVCL_1100, CCRID:1101HUM-PUMC000101, CCRID:1102HUM-NIFDC00093, CCRID:3101HUMTCHu137, CCRID:4201HUM-CCTCC00111, CCTCC:GDC0111, Cell_Model_Passport:SIDM00923, ChEMBL-Cells:ChEMBL3308097, ChEMBL-Targets:ChEMBL1075403, CLS:300145, Cosmic:687507, Cosmic:760221, Cosmic:809232, Cosmic:846182, Cosmic:877469, Cosmic:906824, Cosmic:925357, Cosmic:928904, Cosmic:1019307, Cosmic:1131519, Cosmic:1193033, Cosmic:1201775, Cosmic:1324211, Cosmic:1995364, Cosmic:2060797, Cosmic:2301538, Cosmic:2646655, Cosmic:2660195, Cosmic:2668297, Cosmic:2791017, Cosmic:2816212, Cosmic-CLP:906824, DepMap:ACH-001336, ECACC:87020501, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5_SSTAR:10431-106D8, GDSC:906824, GEO:GSM29720, GEO:GSM113861, GEO:GSM226732, GEO:GSM226867, GEO:GSM253297, GEO:GSM675733, GEO:GSM685445, GEO:GSM722572, GEO:GSM722573, GEO:GSM723053, GEO:GSM723054, GEO:GSM827309, GEO:GSM1669667, IARC_TP53:21261, IBRC:C10345, ICLC:HTL98018, IGRhCellID:CaSki%20GEO, IZSLER:BS TCL 201, JCRB:IFO50007, KCB:KCB 2013034YJ, KCLB:21550, LINCS_HMS:50006, LINCS_LDP:LCL-1541, Lonza:1669, PharmacDB:CaSki_158_2019, PRIDE:PXD030304, Progenetix:CVCL_1100, PubChem_Cell_line:CVCL_1100, RCB:RCB1947, TKG:TKG 0366, Wikidata:Q54808287

ID: CVCL_1100

Record Creation Time: 20220427T215436+0000

Record Last Update: 20260829T231748+0000

Ratings and Alerts

No rating or validation information has been found for Ca Ski.

Warning: Discontinued: ATCC; CRL-7915

Virology: Contains from 100 to 800 copies of the HPV16 genome; some complete and others truncated., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Space-flown cell line (cellonaut).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 247 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lou H, et al. (2026) PIK3CA mutant cervical cancer is selectively suppressed by PI3K? inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy. *Neoplasia* (New York, N.Y.), 76, 101305.

Talpe-Nunes V, et al. (2026) GATA3 Inhibits the Expression of Viral E6/E7 Genes, and Its Expression Is Compromised During HPV-Mediated Cervical Carcinogenesis. *Journal of medical virology*, 98(7), e71034.

Li J, et al. (2026) Alkyltriphenylphosphonium Binding to Cardiolipin Triggers Oncosis in Cancer Cells. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(18), e10237.

Punziano C, et al. (2026) Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation. *Molecular oncology*.

Chhokar A, et al. (2026) Development of a novel multi-locus Flow-FISH based assay for detection of progressive cervical precancer lesions. *BMC cancer*, 26(1).

Jela?i? J, et al. (2026) Gene Expression Profiling and Prognostic Significance of Nuclear and Membrane Progesterone Receptors in Head and Neck Squamous Cell Carcinoma. *International journal of molecular sciences*, 27(4).

Hua Y, et al. (2026) A dual-responsive AI-designed peptide P9-conjugate disrupts E6-E6AP Interface to restore p53 and suppress HPV16-driven cervical cancer. *Journal of controlled release : official journal of the Controlled Release Society*, 390, 114536.

Sandoval TA, et al. (2026) Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer. *Cancer research*, 86(7), 1639.

Lou H, et al. (2026) A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy. *medRxiv : the preprint server for health sciences*.

Zhen Q, et al. (2025) Erucic Acid, Derived by *Lactobacillus Crispatus*, Induces Ferroptosis in Cervical Cancer Organoids Through the PPAR-? Signaling Pathway. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(48), e12599.

Ashraf N, et al. (2025) Factors that determine cell fate in mitotically arrested cancer cells. *Frontiers in cell and developmental biology*, 13, 1691574.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. *Cell reports. Medicine*, 6(11), 102446.

Habbani SF, et al. (2025) Protein Biomarkers Enable Sensitive and Specific Cervical Intraepithelial Neoplasia (CIN) II/III+ Detection: One Step Closer to Universal Cervical Cancer Screening. *Cancers*, 17(11).

Polten R, et al. (2025) Anti-FAP CAR-NK cells as a novel targeted therapy against cervical cancer and cancer-associated fibroblasts. *Oncoimmunology*, 14(1), 2556714.

Flörkemeier I, et al. (2025) Dual Topoisomerase Inhibitor Is Highly Potent and Improves Antitumor Response to Radiotherapy in Cervical Carcinoma. *International journal of molecular sciences*, 26(7).

Horvathova L, et al. (2025) Alphavirus replicons encoding IFN- γ enhance cancer virotherapy by overcoming macrophage-mediated suppression. *iScience*, 28(10), 113545.

Song Y, et al. (2025) Previously undescribed effects and mechanisms of STAT3 in HPV-induced DNA re-replication in response to DNA damage. *The FEBS journal*.

Velimirović M, et al. (2025) Hypoxic HPV-Positive Cancer Cells Are Particularly Sensitive to the Pro-Senescent Effects of B-MYB Repression Due to the Lack of Compensatory A-MYB Induction. *Journal of medical virology*, 97(6), e70422.

Zhang W, et al. (2025) Targeted demethylation of the EphA7 promoter inhibits tumorigenesis via the SP1/DNMT1 and PI3K/AKT axes and improves the response to multiple therapies in cervical cancer. *Cell death & disease*, 16(1), 324.

Pakdel T, et al. (2025) MCPyV small T antigen enhances HPV16 oncogene expression, promotes Ca Ski cell proliferation, and reduces 5-fluorouracil-induced apoptosis in cervical cancer cells. *Infectious medicine*, 4(4), 100222.